CompoAtlas

Collagen OTI Bio Marin

Food supplement declared in France, decision dated 3 November 2026

Collagen OTI Bio Marin (OTI S.r.l. Officine Terapie Innovative) is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
OTI S.r.l. Officine Terapie Innovative
Food business operator placing the product on the market
O.T.I. S.R.L OFFICINE TERAPIE INNOVATIVE
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
3 à 5 gélules par jour
Directions for use
Prendre 3 à 5 gélules par jour avec un verre d’eau.
Intended populations
Men and women aged 18 and over
Not recommended (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Autre : Formation normale de collagène pour assurer la fonction normale des os, des cartilages et de la peau. Cheveux normaux., Enfants (moins de 12 ans), Femmes enceintes
Objectives stated by the manufacturer (these are not authorised claims)
Os, Peau, Articulations, Autre : Formation normale de collagène pour assurer la fonction normale des os, des cartilages et de la peau. Cheveux normaux.

Declaration 381181, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Other active ingredients

NamePer day
Ubiquinonenot declared
Hyaluronate de sodiumnot declared
Collagène marinnot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
D-biotineBiotine (vitamine B8)pas de limite (données insuffisantes)dose annulled by the French Council of State in 2011
Acide L-ascorbiqueVitamine Cpas de limite (données insuffisantes)180 mg
CholécalciférolVitamine D100 µg (4,000 UI)5 µg (200 UI)
Gluconate de zincZinc25 mg15 mg

Additives

E470b

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Ne pas dépasser la dose journalière recommandée. Les compléments alimentaires ne doivent pas être considérés comme un substitut à une alimentation variée et équilibrée et à un mode de vie sain. Tenir hors des jeunes enfants. Réservé à l’adulte. Les femmes enceintes ou allaitantes doivent consulter un professionnel de santé avant toute supplémentation.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Ubiquinone
    Read the warning, when it applies and the studies cited

    Coenzyme Q10 (UBIQUINONE-10)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    Sources cited by Health Canada (2)
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial

    Applies to products providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (3)
    • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 31 January 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : OTI S.r.l. Officine Terapie Innovative

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line